Pramipexole dihydrochloride

A dopamine D2S, D2L, D3, and D4 receptor agonist

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
10mg

￥350.00

280.00

- +
25mg

￥650.00

520.00

- +
50mg

￥1062.00

850.00

- +
100mg

￥1662.00

1330.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajci11492
CAS: 104632-25-9
别名: 盐酸普拉克索
分子式: C10H19Cl2N3S
分子量: 284.25
纯度: >98%
溶解度: ≥ 14.2 mg/mL in DMSO, ≥ 3.43 mg/mL in EtOH with ultrasonic and warming, ≥ 105.2 mg/mL in Water
储存: Store at -20°C
库存: 现货

Background

Pramipexole dihydrochloride is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM for D2S, D2L, D3, D4 receptor, respectively. IC50 Value: 3.9 nM(D2S); 2.2 nM(D2L); 0.5 nM(D3); 5.1 nM(D4)Target: Dopamine ReceptorPramipexole dihydrochloride is a dopamine receptor agonist with selectivity for the D3 receptor (Ki values are 3.9, 3.3, 0.5 and 3.9 nM for D2L, D2S, D3 and D4 receptors respectively). Pramipexole dihydrochloride exhibits negligable affinity for D1 and D5 receptors. Pramipexole has been found to have neuroprotective effects independent of its dopamine receptor agonism. It reduces mitochondrial reactive oxygen species (ROS) production and inhibits the activation of apoptotic pathways. Pramipexole displays activity in the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS).

参考文献:
[1]. Mierau J, Schneider FJ, Ensinger HA et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29-36.
[2]. El-Mallakh RS, Penagaluri P, Kantamneni A et al. Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review. Psychiatr Q. 2010 Sep;81(3):207-13.
[3]. Perez-Lloret S, Rey MV, Ratti L, Rascol O. Pramipexole for the treatment of early Parkinson's disease. Expert Rev Neurother. 2011 Jul;11(7):925-35.
[4]. Hametner EM, Seppi K, Poewe W. Pramipexole extended release in Parkinson's disease. Expert Rev Neurother. 2011 Sep;11(9):1229-34.
[5]. Hametner EM, Seppi K, Poewe W. Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. Clin Interv Aging. 2012;7:83-8.